Xenetic Biosciences reports 2025 net loss $2.7M, cash $7.9M, advances DNase program

Xenetic Biosciences, Inc.

Net loss $2.7M for FY2025; royalty revenue from Takeda sublicense rose 19% to $3.0M.
R&D expenses decreased 7% to $3.1M (excl. prior-year impairment); G&A down 20% to $2.7M.
Ended year with $7.9M cash, up $1.7M from prior year-end, aided by $4.0M October public offering.
Preclinical data supporting DNase I for NETs in cancers; progressing toward IND submission.
Pursuing strategic alternatives to maximize shareholder value.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xenetic Biosciences, Inc. reported the year ended December 31, 2025 results: revenue $3.0 million, net income approximately $2.7 million.

Period: the year ended December 31, 2025
Revenue: $3.0 million
Net income: approximately $2.7 million
Result: reported results

Exact text from the filing

investment in the Company’s most promising scientific programs. Royalty revenue from the Company’s sublicense with Takeda Pharmaceuticals Co. Ltd increased approximately 19% to $3.0 million in the year ended December 31, 2025 from $2.5 million for the year ended December 31, 2024 primarily due to royalty payments received from certain countries. Research and

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-001744

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.